Stryker Corporation: Miss — EPS $3.52, Revenue $6.52B
Earnings MissQ3 2026 · After-market
Did Stryker Corporation (SYK) beat earnings today?
No, Stryker Corporation (SYK) missed Wall Street analyst expectations for Q3 2026, reporting lower-than-expected EPS and lower-than-expected revenue.
Earnings Per Share-0.85% surprise
$3.52Actual
Expected: $3.55
vs. year ago +10.3%
Total Revenue-1.51% surprise
$6.52BActual
Expected: $6.62B
vs. year ago +7.7%
Released Oct 29 · 4:05 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $6.52B | $6.06B | +7.7% |
| Revenue detail — reported lines | |||
| └─MedSurg and Neurotechnology | $3.66B | $3.35B | +9.2% |
| └─Instruments | $996.00M | $949.00M | +5.1% |
| └─Endoscopy | $1.02B | $896.00M | +13.9% |
| └─Medical | $1.08B | $985.00M | +9.7% |
| └─Vascular | $566.00M | $525.00M | +8.0% |
| └─Orthopaedics | $2.86B | $2.70B | +5.7% |
| └─Knees | $635.00M | $628.00M | +1.1% |
| └─Hips | $453.00M | $457.00M | -1.0% |
| └─Trauma and Extremities | $1.01B | $960.00M | +5.3% |
| └─Ortho Tech | $754.00M | $651.00M | +15.8% |
| └─Spinal Implants | $4.00M | $6.00M | -43.9% |
| GAAP Basic EPS | $1.97 | $2.25 | -12.4% |
| GAAP Diluted EPS | $1.96 | $2.22 | -11.7% |
| Adjusted Diluted EPS | $3.52 | $3.19 | +10.3% |
| Net earnings | $753.00M | $859.00M | -12.3% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Outlook |
|---|---|---|
| Organic net sales growth | — | 6.5%-7.0% |
| Adjusted net earnings per diluted share | — | $14.80-$14.90 |
Business Highlights
- ➤Repurchased $1.0B of common stock during the third quarter.
- ➤Board approved a $3.0B increase to the existing share repurchase program.
- ➤Reorganized Ortho Tech to combine Orthopaedic Instruments with Other Orthopaedics.
- ➤Combined Neuro Cranial and Enabling Technologies with the remaining Instruments business.
- ➤Offers products and services across MedSurg, Neurotechnology and Orthopaedics.
- ➤Products and services impact more than 150 million patients annually.
Management Commentary
Kevin A. Lobo, Chair and CEO
“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter. While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.”